Biohaven Ltd. (BHVN) announced positive results from a pivotal study demonstrating the efficacy of troriluzole in slowing the progression of Spinocerebellar Ataxia (SCA). The drug showed statistically significant improvements in f-SARA scores after three years, leading to a potential FDA approval and commercialization in 2025.
Results for: Biohaven
The Dow Jones Industrial Average closed lower on Friday, but some stocks saw significant gains, notably Biohaven Ltd. after positive trial results for its spinocerebellar ataxia treatment. Other notable gainers included BitFuFu, TeraWulf, and Gevo.